Foghorn Therapeutics (FHTX) Capital Expenditures Growth (3y) (2022 - 2026)
Powered by 
Analysis
Foghorn Therapeutics (FHTX) Capital Expenditures Growth (3y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 23.48% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 63.07% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -45.93% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -40.95% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 29.63% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 60.74% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.08% |
| 10 | Foghorn Therapeutics | 347.75 Mn | 279.67 Mn | - | -68.26% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -68.26% |
| Mar 31, 2026 | -61.96% |
| Jun 30, 2025 | -60.76% |
| Mar 31, 2025 | -51.60% |
| Dec 31, 2024 | 81.59% |
| Sep 30, 2024 | 10.34% |
| Jun 30, 2024 | -75.86% |
| Mar 31, 2024 | -61.67% |
| Dec 31, 2023 | -82.97% |
| Sep 30, 2023 | -75.27% |
| Jun 30, 2023 | -36.11% |
| Mar 31, 2023 | -24.38% |
| Dec 31, 2022 | 28.09% |